Evidence map›Paper›PMID 35762075›Full record

SynthesisCardiology journal2022

Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis.

Bartosz Fialek, Michal Pruc, Jacek Smereka, Rafal Jas, Mansur Rahnama-Hezavah, Andrea Denegri, Agnieszka Szarpak, Milosz J Jaguszewski, Frank W Peacock, Lukasz Szarpak

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Cardiology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Bartosz FialekRheumatology Department, Marshal Jozef Pilsudski Memorial Hospital, Plonsk, Poland.ORCID 0000-0002-0894-5813
Michal PrucResearch Unit, Polish Society of Disaster Medicine, Warsaw, Poland.ORCID 0000-0002-2140-9732
Jacek SmerekaResearch Unit, Polish Society of Disaster Medicine, Warsaw, Poland.ORCID 0000-0002-1427-4796
Rafal JasStudents Research Club, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.ORCID 0000-0002-6659-9058
Mansur Rahnama-HezavahChair and Department of Oral Surgery, Medical University of Lublin, Lublin, Poland.ORCID 0000-0002-5622-7330
Andrea DenegriParma University Hospital, Parma, Italy.ORCID 0000-0001-5283-3176
Agnieszka SzarpakInstitute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.ORCID 0000-0002-6196-6111
Milosz J Jaguszewski1st Department of Cardiology, Medical University of Gdansk, Poland.ORCID 0000-0003-2032-7484
Frank W PeacockHenry JN Taub Department of Emergency Medicine, Baylor College of Medicine Houston, Houston, TX, United States.
Lukasz SzarpakHenry JN Taub Department of Emergency Medicine, Baylor College of Medicine Houston, Houston, TX, United States. lukasz.szarpak@gmail.com.ORCID 0000-0002-0973-5455
Baylor College of Medicine · USGdańsk Medical University · PLJózef Piłsudski University of Physical Education in Warsaw · PLMedical University of Lublin · PLUniversity of Parma · ITWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis meta-analysis outlines the role of elevated lactate dehydrogenase (LDH) levels in assessing the severity of coronavirus disease 2019 (COVID-19).

methodsThe current study was designed as a systematic review and meta-analysis. Embase, Pub- Med, Web of Science, Scopus and Cochrane Central Register of Controlled Trials were searched to identify the usefulness of LDH as a marker of COVID-19 severity. All extracted data were analyzed using RevMan V.5.4 or STATA V.14 software.

resultsA total of 264 records were selected for this meta-analysis. Pooled analysis showed that LDH levels were statistically significantly lower in the group of survivors compared to patients who died in hospital (standardized mean differences [SMD] = -3.10; 95% confidence interval [CI]: -3.40 to -2.79; I2 = 99%; p < 0.001). Lower LDH levels were observed in non-severe groups compared to severe course of COVID-19 (SMD = -2.38; 95% CI: -2.61 to -2.14; I2 = 99%; p < 0.001). The level of LDH was statistically significantly lower in the severe group compared to the critical group (SMD = -1.48; 95% CI: -2.04 to -0.92; I2 = 98%; p < 0.001). Patients who did not require treatment in the intensive care unit (ICU) showed significantly lower levels of LDH compared to patients who required treatment in the ICU (SMD = -3.78; 95% CI: -4.48 to -3.08; I2 = 100%; p < 0.001).

conclusionsThis meta-analysis showed that elevated LDH was associated with a poor outcome in COVID-19.

Indexed as

COVID-19BiomarkersCOVID-19 TestingHumansL-Lactate DehydrogenaseBiomarkersL-Lactate DehydrogenaseCOVID-19lactate dehydrogenaseLDHmarkermeta-analysisSARS-CoV-2severity

Identifiers

PMID35762075
PMCPMC9550334
OpenAlexW4283643878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.